Platform Technologies Patents
US Patent no. US 8,9 01, 129 B2, Date of Patent: Dec 2, 2014, European Patent no. E P 25099 53, March 30, 2016
“METHODS OF FACILITATING NEURAL CELL SURVIVAL USING GDNF FAMILY LIGAND (GFL) MIMETICS OR RET SIGNALING PATHWAY ACTIVATORS”
The diseases targeted by this GENECODE Patent protected invention are listed in the background information of the Patent, section (0014):
 The disorders targeted by the present invention include Alzheimer s disease, Huntington’s disease, amyotrophic lateral sclerosis, Rett syndrome, epilepsy, Parkinson’s disease, spinal cord injury, stroke, hypoxia, ischemia, brain injury, diabetic neuropathy, peripheral neuropathy, nerve transplantation complications, motor neuron disease, multiple sclerosis, HIV, dementia, peripheral nerve injury, hearing loss, depression, obesity, metabolic syndrome, pain, cancer and other conditions involving degeneration or dysfunction of cells expressing GFR α /RET.
US Patent no. US 7,78 6, 292 B2, Date of Patent: Aug 31, 2010, European Patent no. EP 2013 044, Aug 29, 2012
“ANTISENSE AGENTS COMBINING STRONGLY BOUNDING BASE-MODIFIED OLIGONUCLEOTIDE AND ARTIFICIAL NUCLEASE.”
The diseases targeted by this GENECODE’s Patent protected invention are listed in the background information of the Patent:
The specific binding of antisense oligonucleotides to the DNA or RNA targets can inactivate the replication, transcription or translation of nucleic acids, thereby providing a mechanism for controlling diseases such as cancer and viral infection. The binding of antisense oligonucleotide to a target can thus be used to alter gene expression in a variety of circumstances, for example, to interfere with viral life cycles or the growth of cancerous cells.